Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Baden – page 49

865 clinical trials in Baden, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Baden at a glance
865
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

865 trials in Baden

Open in trial search

Study on BI 1839100 for Reducing Cough in Patients with Idiopathic or Progressive Pulmonary Fibrosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BI 1839100
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on Anifrolumab for Adults with Chronic or Subacute Cutaneous Lupus Erythematosus Unresponsive to Antimalarial Therapy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:Astrazeneca AB

Study on BI 1819479 to Improve Lung Function in Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BI 1819479
  • Sponsor:Boehringer Ingelheim Espana S.A.

Neuroendocrine tumour

Not recruiting

Study of Cabozantinib in Adults with Advanced Low-Grade Neuroendocrine Tumors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Universitaetsmedizin Goettingen

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Sonelokimab for Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Fallopian tube cancer+2

Not recruiting

Study of Nemvaleukin Alfa and Pembrolizumab for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Nemvaleukin Alfa
  • Sponsor:Mural Oncology Inc.

Plasma cell myeloma

Not recruiting

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Pfizer Inc.

Study on the Effects of Satralizumab for Patients with Autoimmune Encephalitis (NMDAR or LGI1)

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Myasthenia gravis

Not recruiting

Study on the Effects of Efgartigimod Alfa for Patients with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Ventricular drainage

Not recruiting

Study on How Antibiotics Work in the Spinal Fluid of Children with Brain Drains: Cefuroxime, Vancomycin, and Gentamicin with a Drug Combination

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Ampicillin Sodium
  • Sponsor:Medical University Of Vienna

Breast cancer

Not recruiting

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Astrazeneca AB

Study on Long-Term Safety and Effectiveness of Treprostinil Palmitil for Patients with Pulmonary Arterial Hypertension

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Baden

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on hormone receptor-positive (HR+) and HER2-negative breast cancer evaluating personalized treatment approaches using targeted therapies.

  • Adjuvant therapy optimization
  • Personalized treatment strategies
  • Novel drug combinations

Studies aim to improve survival rates through dynamic marker-adjusted therapeutic approaches.

02 Triple-Negative Breast Cancer

Research examining neoadjuvant treatment options for patients with early-stage triple-negative breast cancer, comparing innovative therapeutic combinations.

  • Treatment response assessment
  • Immunotherapy combinations
  • Survival outcome evaluation

Focus on improving treatment efficacy in low-risk recurrence patients.

03 Ovarian Cancer Studies

Advanced research on HRD-positive high-grade ovarian cancer, investigating optimized treatment durations and maintenance therapy approaches.

  • Chemotherapy optimization
  • Maintenance therapy evaluation
  • Recurrence prevention strategies

Emphasis on improving outcomes for patients with no residual tumor after debulking surgery.

04 Leukemia Research

Groundbreaking studies in chronic lymphocytic leukemia (CLL) examining novel drug combinations for high-risk patients.

  • Targeted therapy combinations
  • High-risk patient treatment
  • Disease progression prevention

Investigation of innovative triple-combination therapies for improved patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.